HutchMed highlights that results from the SACHI Phase III trial were published in The Lancet. SACHI is a Phase III study of the savolitinib (Orpathys) and osimertinib (Tagrisso )… read more.
A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute has developed and validated an artificial intelligence (AI)–based noninvasive tool that can predict the likelihood that a… read more.
Caris Life Sciences announced that its therapeutic research arm, Caris Discovery, has entered into a multi-year collaboration and license agreement with Genentech, a member of the Roche Group. In… read more.
Guardant Health Inc. announced new data demonstrating that its Guardant Reveal blood test helps clinicians to assess the effectiveness of chemotherapy in patients with advanced solid tumors months… read more.
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumours, while reducing side effects. This is reported by researchers… read more.
Treating malignant melanoma with lower doses of approved immunotherapy appears to result in improved results, while also reducing side effects. Investigators from the Karolinska Institutet in Stockholm, Sweden… read more.
Some blood pressure medications can make the skin extra prone to sunburn. A registry study from Lund University in Sweden shows a possible increased risk of basal cell… read more.
NICE (UK): Darolutamide with androgen deprivation therapy (ADT) can be used as an option to treat hormone-sensitive metastatic prostate cancer in adults, only if: i) docetaxel is not… read more.
VolitionRx Limited, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently. The posters highlighted the use of its Nu.Q® Cancer… read more.
Researchers report that an analysis of data from outpatient facilities in the New York State region revealed that 20-24% of breast cancers breast cancers diagnosed in an 11-year… read more.
AstraZeneca advances its ambition to redefine haematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and… read more.
Eli Lilly and Company announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will be presented at the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
